Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,546.38
(
-0.91%
)
US TECH 100
23,462.40
(
-1.09%
)
Dow Jones
45,728.11
(
-0.64%
)
Brent Oil
106.71
(
2.18%
)
Bitcoin
69,709.64
(
-0.27%
)
News Focus
News Focus
Post# of 1367
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: midastouch017 post# 548

Wednesday, 09/27/2006 7:47:26 AM

Wednesday, September 27, 2006 7:47:26 AM

Post# of 1367
> Quark Biotech – "We paid more than $95 million in royalties to two companies for the purchase of a license for drugs that we developed… That is why the deal with Pfizer is worth hundreds of millions of dollars,"<

These two companies are SR Pharma (#msg-13597890) and ALNY (#msg-13575078). From the contents of these two PR’s, it appears that SR Pharma is the main sublicensing beneficiary and ALNY’s take is small.

Still, no matter how you slice it the PFE-Quark deal is a big story for RNAi (and for Israel).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today